New York, NY – According to filings with the U.S. Securities and Exchange Commission, Reset Pharmaceuticals is raising $12,714,610.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jan-Anders Karlsson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Reset Pharmaceuticals
Reset Pharma is a privately-held biotechnology company focused on the development and commercialization of novel psychedelic treatments for patients with life-threatening illnesses, including cancer. The company’s lead program focuses on psilocybin with psychotherapy for patients with cancer related demoralization, anxiety and depression. Reset Pharma has established a highly experienced biotech development team and has a Scientific Advisory Board of leading experts in psychiatry, oncology and psychedelics.

To learn more about Reset Pharmaceuticals, visit http://www.resetpharma.com/

Contact:
Jan-Anders Karlsson, President and Chief Executive Officer
646-342-2583
jkarlsson@resetpharma.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved